PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-153.78%
Negative net income growth while CRON.TO stands at 84.93%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-9.32%
Negative yoy D&A while CRON.TO is 17.05%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
198.53%
Lower deferred tax growth vs. CRON.TO's 615.76%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
-49.49%
Negative yoy SBC while CRON.TO is 23.69%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-34.37%
Both reduce yoy usage, with CRON.TO at -343.66%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-84825.99%
Both negative yoy, with CRON.TO at -104.12%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-100.98%
Both yoy CFO lines are negative, with CRON.TO at -209.80%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-28.69%
Both yoy lines negative, with CRON.TO at -116.27%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
214.58%
Less M&A spending yoy vs. CRON.TO's 2265455282194.23%, reducing near-term risk. David Dodd would confirm the firm is not missing out on a strategic deal that competitor might exploit.
-23.52%
Negative yoy purchasing while CRON.TO stands at 101.36%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
-53.91%
We reduce yoy sales while CRON.TO is 64.88%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-1612.57%
We reduce yoy other investing while CRON.TO is 102.73%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-47.75%
Both yoy lines negative, with CRON.TO at -64.73%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
7.64%
Debt repayment growth of 7.64% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
39.77%
Stock issuance far above CRON.TO's 31.84%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.